SONN (Sonnet BioTherapeutics Holdings, Inc.) Stock Market Reviews

crown

search

Read and share opinions on SONN (Sonnet BioTherapeutics Holdings, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the

SONN

Sonnet BioTherapeutics Holdings, Inc.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma
Oct 15, 2025
Sonnet to Present at the MedInvest Biotech & Pharma Conference
Sep 19, 2025
Sonnet Releases Virtual Investor "What This Means" Segment
Aug 11, 2025
Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer
Aug 4, 2025
Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit
May 1, 2025
Sonnet Announces Release of Corporate Update Video
Apr 1, 2025
Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.
Apr 1, 2025
Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein
Mar 19, 2025
Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
Mar 11, 2025
Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors
Feb 26, 2025
Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates
Feb 19, 2025
Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference
Feb 18, 2025
Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer
Feb 13, 2025

Reviews